HIGHLIGHTS
- who: Report and collaborators from the Neurological Institute, Phoenix, USA, Baylor Scott and White Medical Center, Temple, USA , have published the article: Review began 08/11/2022 Review ended 08/17/2022 Published 08/19/2022 u00a9 Copyright, in the Journal: (JOURNAL) of August/19,/2022
- what: Based on our measured parameters, ONC201 has demonstrated safety and efficacy in subjects receiving the study drug against H3K27M-mutant malignant glioma.
- how: Characteristics of cases in this study are presented in Table 1.
SUMMARY
ONC201 is a small_molecule, orally active having . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.